NOMAD POWER SOLUTIONS, INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
NOMAD POWER SOLUTIONS, INC. (NMAD) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $24.99 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $24.99M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $9.18M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $10.96M.
- 2025-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $651.46K.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $24.99M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $9.18M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $10.96M 10-Q · filed 2026-08-14 |
| 2025-06-30 | $651.46K 10-Q · filed 2026-08-14 |
| 2025-03-31 | $1.16M 10-Q · filed 2026-08-14 |
| 2024-12-31 | $827.22K 10-Q · filed 2026-08-14 |
| 2023-12-31 | $3.99M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B |